Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $22,000 | 1 | 75.0% |
| Unspecified | $7,282 | 4 | 24.8% |
| Food and Beverage | $65.45 | 2 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sensus Healthcare, Inc. | $22,000 | 1 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $7,282 | 4 | $0 (2023) |
| Hu-Friedy Mfg. Co., LLC | $48.05 | 1 | $0 (2019) |
| ABBVIE INC. | $17.40 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $6,663 | 2 | Novartis Pharmaceuticals Corporation ($6,663) |
| 2022 | $636.40 | 3 | NOVARTIS PHARMACEUTICALS CORPORATION ($619.00) |
| 2020 | $22,000 | 1 | Sensus Healthcare, Inc. ($22,000) |
| 2019 | $48.05 | 1 | Hu-Friedy Mfg. Co., LLC ($48.05) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/09/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | Cash or cash equivalent | $509.29 | Research |
| Study: BYL-AB -117225-Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (ABC) treated with alpelisib (ALP)-FALLCDC • Category: Oncology | ||||||
| 01/31/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug) | — | Cash or cash equivalent | $6,153.93 | Research |
| Study: Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated with Alpelisib-Breast Cancer Res Treat • Category: Oncology | ||||||
| 09/30/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | PIQRAY (Drug) | — | In-kind items and services | $443.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 09/17/2022 | ABBVIE INC. | DUOPA (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: NEUROSCIENCE | ||||||
| 06/14/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | PIQRAY (Drug) | — | In-kind items and services | $176.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH • Category: ONCOLOGY | ||||||
| 01/24/2020 | Sensus Healthcare, Inc. | — | Honoraria | Cash or cash equivalent | $22,000.00 | General |
| 08/01/2019 | Hu-Friedy Mfg. Co., LLC | Karl Schumacher Syringes (Device) | Food and Beverage | In-kind items and services | $48.05 | General |
| Category: Dental and Oral Health | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated with Alpelisib-Breast Cancer Res Treat | Novartis Pharmaceuticals Corporation | $6,154 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $619.00 | 2 |
| BYL-AB -117225-Expert consensus recommendations for managing hyperglycemia and rash in patients with PIK3CA-mutated, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (ABC) treated with alpelisib (ALP)-FALLCDC | Novartis Pharmaceuticals Corporation | $509.29 | 1 |
About Brian Berman
Brian Berman is a Specialist healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124061247.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Brian Berman has received a total of $29,348 in payments from pharmaceutical and medical device companies, with $6,663 received in 2023. These payments were reported across 7 transactions from 4 companies. The most common payment nature is "Honoraria" ($22,000).
Practice Information
- Specialty Specialist
- Location Baltimore, MD
- Active Since 06/14/2006
- Last Updated 07/08/2007
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1124061247
Products in Payments
- PIQRAY (Drug) $7,282
- Karl Schumacher Syringes (Device) $48.05
- DUOPA (Drug) $17.40
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Baltimore
Mr. James Gammie, M.d, M.D
Specialist — Payments: $29.8M
Dr. Richard Adler, M.d, M.D
Specialist — Payments: $3.1M
Dr. Philip Levin, M.d, M.D
Specialist — Payments: $921,481
Dr. Agha Khan, Md, MD
Specialist — Payments: $170,581
W. Eglseder, M.d, M.D
Specialist — Payments: $57,679
Bartley Griffith, M.d, M.D
Specialist — Payments: $49,695